ROTHBLATT MARTINE A sold $5.1M of UTHR
ROTHBLATT MARTINE A (Chairperson & CEO) sold 9,500 shares of UNITED THERAPEUTICS Corp (UTHR) at an average of $535.99 ($533.70–$542.80, $5.09M total) across 9 trades on 2026-07-13 under a Rule 10b5-1 trading plan.
How this was made
The 30-second read
Why it matters
The CEO-chair executed an open-market sale totaling about $5.09M across multiple trades at roughly $534 to $543 per share, with holdings after the sale of 40,513 shares.
Market read
Primarily a sentiment/positioning datapoint for UTHR, with limited fundamental implications absent other catalysts.
What to watch
Traders may over-weight insider sales; the key nuance here is the pre-arranged 10b5-1 plan and the lack of accompanying operational disclosures.
Background
The article is an SEC Form 4 insider transaction disclosure for United Therapeutics (UTHR).
Ticker impact
United Therapeutics CEO and chair Martine Rothblatt sold $5.09M of UTHR shares in an open-market transaction under a 10b5-1 plan on July 13.
Near-term impact likely limited; any reaction should fade unless accompanied by other company-specific catalysts.
The filing is a primary SEC Form 4 disclosure with transaction size and pricing, but it does not include new guidance, trial results, or regulatory/product developments.
Market effects
No direct sector read-through; insider sales are company-specific sentiment signals.
None indicated.
None indicated.
Counterpoint
A 10b5-1 sale can be routine liquidity planning and may not reflect bearish fundamentals; price may ignore it if no other news emerges.
Key entities
- issuerUnited Therapeutics Corp
Company whose insider transaction is disclosed on SEC Form 4.
- insiderMartine A. Rothblatt
Chairperson and CEO who sold shares under a 10b5-1 plan.
